BackgroundCheck.run
Search For

Guy A Zimmerman, 639622 S Channing Dr, South Jordan, UT 84095

Known as:
Guy Alan Zimmerman Guy A Adams
Related to:
Anne S Zimmerman 57

Guy Zimmerman Phones & Addresses

9622 S Channing Dr, South Jordan, UT 84095    801-9494045   

6479 Clematis Way, West Jordan, UT 84084   

Redlands, CA   

Harbor City, CA   

San Pedro, CA   

Work

Company: Milner hotel Address: 813 S Flower St, Los Angeles, CA 90017 Phones: 213-6276981 Position: Manager Industries: Hotels and Motels
Get Report
Control this profile

Mentions for Guy A Zimmerman

Career records & work history

Medicine Doctors

Guy Zimmerman Photo 1

Guy Zimmerman, Salt Lake City UT

Work:
Uumc Pulmonary Dept
50 N Medical Dr, Salt Lake City, UT 84132

License Records

Guy A Zimmerman

Address:
Riverton, UT
Licenses:
License #: 262523-3102 - Active
Category: Nurse
Issued Date: Apr 23, 1993
Expiration Date: Jan 31, 2017
Type: Registered Nurse (Under Interstate Compact)

Guy D Zimmerman

Licenses:
License #: 2705001162 - Expired
Category: Contractor
Issued Date: Apr 29, 1991
Expiration Date: Apr 30, 2009
Type: Class B

Guy Zimmerman resumes & CV records

Resumes

Guy Zimmerman Photo 38

Quality Manager At Chg Healthcare

Position:
Quality Management Supervisor at CHG Healthcare Services
Location:
Greater Salt Lake City Area
Industry:
Hospital & Health Care
Work:
CHG Healthcare Services since Nov 2010
Quality Management Supervisor Jordan Valley Medical Center Oct 2009 - May 2010
NURSE CASE MANAGER COZY Home Healthcare & Hospice Dec 2007 - Oct 2009
NURSE CASE MANAGER Highland Ridge Hospital, Pioneer Behavioral Health, Inc. Aug 2006 - Dec 2007
DIrector of Nursing Salt Lake Regional Medical Center May 2005 - May 2006
CASE MANAGER Zurich North America Insurance Apr 2002 - Apr 2005
NURSE CONSULTANT / KEY ACCOUNT MANAGEMENT Pioneer Valley Hospital ER (IASIS) Jul 2000 - Dec 2002
CHARGE RN Rocky Mountain Medical Center (IASIS) Feb 2000 - Jul 2000
DIRECTOR OF EMERGENCY SERVICES Pioneer Valley Hospital ER (IASIS) Apr 1998 - Feb 2000
CHARGE RN Columbia Home Care Jan 1997 - Apr 1998
CLINICAL COORDINATOR HOME INFUSION SERVICES Aug 1996 - Jan 1997
DIRECTOR FHP HOME HEALTH May 1996 - Aug 1996
CASE MANAGER FHP HOSPITAL Jul 1993 - Jun 1996
CHARGE NURSE INTENSIVE CARE & EMERGENCY ROOM Loma Linda University Medical Center Jun 1989 - Apr 1993
RN, CHARGE NURSE, CARDIAC ICU
Education:
Marylhurst University 2015
Master of Business Administration (MBA), Business Administration and Management, General University of Phoenix 2001 - 2003
BS, Business/Marketing Los Angeles Harbor College 1986 - 1989
ADN, Registered Nurse
Guy Zimmerman Photo 39

Artistic Director, Padua Playwrights; Associate Editor/Writer, Times Quotidian; Phd Candidate, Uc Irvine, Drama

Position:
Associate Editor and Feature Writer at Times Quotidian, Artistic Director at Padua Playwrights
Location:
Los Angeles, California
Industry:
Performing Arts
Work:
Times Quotidian - Los Angeles since 2009
Associate Editor and Feature Writer Padua Playwrights - Los Angeles since 2001
Artistic Director
Education:
University of Pennsylvania 1978 - 1982
BA, European History, Art History University of California, Irvine 2011
Phd, Dramatic Arts and Theater
Guy Zimmerman Photo 40

Professor Of Medicine At University Of Utah

Position:
Professor of Medicine at University of Utah
Location:
Greater Salt Lake City Area
Industry:
Market Research
Work:
University of Utah
Professor of Medicine

Publications & IP owners

Us Patents

Use Of Pre-Mrna Splicing In Platelet Cells For The Diagnosis Of Disease

US Patent:
2010029, Nov 25, 2010
Filed:
Jun 20, 2008
Appl. No.:
12/452333
Inventors:
Andrew S. Weyrich - Salt Lake City UT, US
Hansjorg Schwertz - Salt Lake City UT, US
Guy Zimmerman - Salt Lake City UT, US
Neal Tolley - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (≧65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death.

Terminally-Differentiated Anucleate Platelet Progeny Generation

US Patent:
2011029, Dec 1, 2011
Filed:
Oct 7, 2009
Appl. No.:
13/122886
Inventors:
Hansjorg Schwertz - Salt Lake City UT, US
Robert C. Blaylock - Salt Lake City UT, US
Larry W. Kraiss - Salt Lake City UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
International Classification:
A61K 38/02
A61K 31/7072
A61K 31/551
A61K 31/496
A61K 31/536
A61P 7/00
A61K 31/203
A61K 31/708
A61K 31/7068
A61K 31/513
A61K 31/52
C12N 5/078
A61K 31/505
US Classification:
514 135, 435325, 435391, 514 50, 514220, 51425309, 5142305, 514272, 514559, 514 45, 514 49, 514274, 5142634
Abstract:
Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic use for RT inhibitors that can now be used for treatment of thrombocytopenia and related disorders. Likewise, application of soluble protein factor that may be secreted and/or released by platelets cultured under thrombocytopenic conditions may also be used as a therapeutic agent to increase platelet numbers.

Signal-Dependent Splicing Of Tissue Factor Pre-Mrna In Platelet Cells

US Patent:
2009004, Feb 12, 2009
Filed:
Jun 20, 2008
Appl. No.:
12/143645
Inventors:
Andrew S. Weyrich - Salt Lake City UT, US
Hansjorg Schwertz - Salt Lake City UT, US
Guy Zimmerman - Salt Lake City UT, US
Neal Tolley - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 31/54
C12Q 1/68
C40B 30/06
G01N 33/00
A61P 7/00
C40B 30/08
C12Q 1/02
US Classification:
5142242, 435 6, 506 10, 436 86, 506 11, 435 29
Abstract:
The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from, disordered coagulation.

Nnif And Nnif-Related Peptides And Related Methods

US Patent:
2021013, May 13, 2021
Filed:
Jun 22, 2020
Appl. No.:
16/908250
Inventors:
- SALT LAKE CITY UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
Joshua Schiffman - Salt Lake City UT, US
International Classification:
A61K 38/17
C07K 14/47
A61P 29/00
A61P 35/04
Abstract:
Neonatal NET-inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.

Methods For Treatment Of And Prophylaxis Against Inflammatory Disorders

US Patent:
2020027, Sep 3, 2020
Filed:
Apr 6, 2020
Appl. No.:
16/841221
Inventors:
- Salt Lake City UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
International Classification:
A61K 38/57
A61K 38/17
C07K 14/47
Abstract:
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

Methods For Treatment Of And Prophylaxis Against Inflammatory Disorders

US Patent:
2019030, Oct 10, 2019
Filed:
Jan 23, 2019
Appl. No.:
16/255545
Inventors:
- North Salt Lake UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
International Classification:
A61K 38/57
C07K 14/47
A61K 38/17
Abstract:
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

Methods For Treatment Of And Prophylaxis Against Inflammatory Disorders

US Patent:
2017023, Aug 17, 2017
Filed:
Feb 24, 2017
Appl. No.:
15/441982
Inventors:
- Salt Lake City UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
International Classification:
A61K 38/57
Abstract:
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

Methods For Treatment Of And Prophylaxis Against Inflammatory Disorders

US Patent:
2016019, Jul 7, 2016
Filed:
Jul 7, 2014
Appl. No.:
14/904048
Inventors:
- Salt Lake City UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US
International Classification:
C07K 14/47
A61K 47/48
Abstract:
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

Isbn (Books And Publications)

The Lung In Rheumatic Diseases

Author:
Guy A. Zimmerman
ISBN #:
0824782119

Possible Relatives

Cynthia M Zimmerman  David R Zimmerman  Dax Zimmerman  Dean W Zimmerman  Deanna Zimmerman  Daisy B Zimmerman  Dale E Zimmerman  Guy D Johnson  Guy L Johnston  Guy W White 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.